Program - Society of Toxicology

50 th Anniversary Annual Meeting and ToxExpo
Program Description (Continued)
Wednesday
Abstract # Abstract #
#2504 4:30 ASSESSMENT OF NANOPARTICLE
EXPOSURE IN OCCUPATIONAL SETTINGS
AND IN INHALATION TOXICOLOGY
STUDIES: IS THERE A BEST DOSEMETRIC
TO USE? ​D. B. Warheit 1 and G. Oberdorster 2 .
1
DuPont Haskell Global Centers, Wilmington, DE
and 2 University of Rochester, Rochester, NY.
4:30 INTRODUCTION. ​David B. Warheit
4:40 A CHANGE IN DOSE METRICS FOR
INHALATION TOXICITY STUDIES WITH
ENGINEERED NANOPARTICLES. ​David B.
Warheit
4:50 THE MERITS OF USING SURFACE AREA
METRICS BASED ON MEASUREMENTS
OF PARTICLE NUMBERS AND MATERIAL-
SPECIFIC DENSITY FOR QUANTIFYING
PARTICLE EXPOSURES. ​Günter Oberdӧrster
5:00 REAL-TIME INSTRUMENTATION FOR
MEASURING AIRBORNE PARTICLE
SURFACE AREA AND MORPHOLOGY OF
NANOPARTICLE AGGLOMERATES. ​David
Y. Pui
5:10 THE EFFECT OF AGGLOMERATE
STRUCTURE SIZE ON THE BIOACTIVITY
OF NANOPARTICLES. ​Vincent Castranova
5:20 PANEL DISCUSSION/Q&A.
Wednesday Afternoon, March 9
4:30 PM to 5:50 PM
Room 143
Toxicity Testing: State of Science and Strategies to
Improve Public Health
Informational Session: Progress of the Tox21 Consortium in
High-Throughput Bioactivity Profiling of Chemicals
Chairperson(s): Robert Kavlock, U.S. EPA, Research Triangle Park, NC,
and Chris Austin, National Human Genome Research Institute, Bethesda,
MD.
Sponsor:
In Vitro and Alternative Methods Specialty Section
Endorsed by:
Mechanisms Specialty Section
Molecular Biology Specialty Section
Risk Assessment Specialty Section
In 2008, the National Institute of Environmental Health Sciences/National
Toxicology Program, the NIH Chemical Genomics Center, and the U.S.
EPA’s National Center for Computational Toxicology entered into a Memorandum
of Understanding to collaborate on the research, development,
validation, and translation of new and innovative test methods to characterize
key steps in toxicity pathways. The U.S. FDA joined this consortium
in 2010. A central component is the exploration of high-throughput
screening, as well as high-throughput whole genome analytical methods,
to evaluate mechanisms of toxicity. The goals of the Tox21 Community are
to investigate the use of these new tools, along with existing chemical and
biological information, to prioritize substances for further in-Department
toxicological evaluation, identify mechanisms of action for further investigation,
and develop predictive models for in vivo biological response.
Success is expected to result in test methods for toxicity testing that are
more mechanistically based and economically efficient; as a consequence,
a reduction or replacement of animals in regulatory testing is anticipated to
occur in parallel with an increased ability to evaluate the large numbers of
chemicals that currently lack adequate toxicological evaluation. In the past
year, Tox21 has completed assembly of a library of ~10, 000 chemicals and
338
began screening the library against molecular targets and pathways at the
rate of one assay per week. Our panel of experts will inform the scientific
community of progress in meeting the Tox21 goals, by focusing on the strategies
for chemical and assay selection, workflows for data management and
analysis, and understanding the human significance of results. The Tox21
effort represents the largest and most comprehensive evaluation of interaction
of environmental chemicals with toxicity pathways and is helping to
pave the way for the use of high-throughput screening tools in hazard identification,
chemical prioritization, and risk assessment.
#2505 4:30 PROGRESS OF THE TOX21 CONSORTIUM
IN HIGH-THROUGHPUT BIOACTIVITY
PROFILING OF CHEMICALS. ​R. Kavlock 1 and
C. Austin 2 . 1 U.S. EPA, Research Triangle Park, NC
and 2 NIH Chemical Genomics Center, Gaithersburg,
MD.
4:30 INTRODUCTION. ​Chris Austin
4:35 THE STRATEGY FOR DESIGN OF THE
10,000 CHEMICAL LIBRARY AND
CHEMOINFORMATIC
CHARACTERIZATION. ​Ann Richard
4:53 THE STRATEGY FOR ASSAY SELECTION
AND ASSAY QUEUE. ​Kristine Witt
5:11 INFORMATIC APPROACHES TO ANALYSIS
OF 10K CHEMICAL LIBRARY. ​Ruili Huang
5:29 USING HUMAN DATA TO UNDERSTAND
AND INTERPRET TOX21 SCREENING
RESULTS. ​David Jacobson-Kram
5:47 CLOSING REMARKS. ​Robert Kavlock
Wednesday Afternoon, March 9
4:30 PM to 5:50 PM
Room 145
Informational Session: Toxicological Considerations of
Pharmacotherapy during Pregnancy
Chairperson(s): Susan Laffan, GlaxoSmithKline, King of Prussia, PA, and
Ofelia Olivero, National Cancer Institute, Bethesda, MD.
Sponsor:
Women in Toxicology Special Interest Group
Endorsed by:
Regulatory and Safety Evaluation Specialty Section
Reproductive and Developmental Toxicology Specialty Section
Pharmacotherapy of pregnant women is challenging and requires considerations
for the mother and the fetus. Almost every pregnant woman is
exposed to some type of medication during pregnancy. Many pregnant
women refuse medically important agents or conversely, are prescribed
drugs deemed safe despite evidence of possible teratogenicity and/or genotoxicity.
An overview of the proposed new pregnancy labeling categories
based on reproductive toxicology and present results of pharmacokinetic
studies in pregnant women funded by the U.S. FDA Office of Women’s
Health will be provided. It is therefore important to offer a medical perspective
on the challenges involved in treating pregnant and lactating women as
a population and as individuals. This process, known as theranostics, will
be useful and allow U.S. to tailor medical treatments for individual patients.
Because of this process we can focus on maternal pharmacotherapy and
role of the placenta in modulation and transfer of agents to the conceptus.
In addition, we will be able to examine a range of in vitro assessments for
studying the human placenta and animal models as well as investigating
maternal and fetal advantages of novel nanomedicines. To fully assess the
issue of phamacotherapy, it is important to discuss the unique challenges of
supporting clinical trials in pregnant women while developing a novel medicine
for preterm labor. Finally, research on the transplacental carcinogenicity
Education-Career Development Sessions
Exhibitor Hosted Sessions
Featured Sessions
Historical Highlights
Informational Sessions
Platform Sessions